<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="145211">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01210274</url>
  </required_header>
  <id_info>
    <org_study_id>10-PP-10</org_study_id>
    <nct_id>NCT01210274</nct_id>
  </id_info>
  <brief_title>Characterization of the Mechanisms of Resistance to Azacitidine</brief_title>
  <official_title>Characterization of the Mechanisms of Action of Resistance to Azacitidine in High-risk Myelodysplastic Syndromes and Acute Myeloid Leukemia With Multilineage Dysplasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nice</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nice</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Myelodysplastic syndromes (MDS) are frequent diseases in elderly patients (median age: 71
      years). IPSS classification defines low risk (Low and Intermediate 1), and high risk
      (Intermediate 2 and High) MDS. High-risk MDS (MDS-HR) have a high risk of transformation
      into acute leukemia with multilineage dysplasia (AML-DML). The success of Azacitidine has
      been mainly achieved through a rigorous empirical and clinical research, but the molecular
      mechanisms by which this molecule exerts its effects remain poorly characterized. The
      primary mode of action of Azacytidine is through DNA demethylation, and integration in to
      mRNA that favor traduction inhibition. The impact of this molecule on various cell death
      programs involved in the elimination of leukemic cells : apoptosis and autophagy is
      currently poorly known.

      The research program and clinical studies we proposed focus on two major aspects:

      - Main objective: Molecular mechanism of action and resistance to Azacitidine: Role of
      apoptosis versus autophagy.

      - Secondary Objective: Reversion of Azacytidine resistance using different drugs targeting
      apoptosis and/or autophagy. Our laboratory has identified new molecules to selectively
      induce different types of cell death (apoptosis or autophagy).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>hematological response</measure>
    <time_frame>at 3 months</time_frame>
    <description>Hematological response evaluated by the International Working Group (IWG) response of Cheson</description>
  </primary_outcome>
  <primary_outcome>
    <measure>hematological response</measure>
    <time_frame>at 6 months</time_frame>
    <description>Hematological response evaluated by the International Working Group (IWG) response of Cheson</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Day 1 of treatment</time_frame>
    <description>Overall survival (OS) defined as the time from start of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>at the death</time_frame>
    <description>Overall survival (OS) defined as the time from start of treatment</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Myelodysplastic Syndromes or Acute Myeloid Leukemia With Multilineage Dysplasia</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      bone marrow samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with myelodysplastic syndromes or acute myeloid leukemia with multilineage
        dysplasia treated with Azacitidine
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years

          -  High Risk or Intermediate 2 MDS (IPSS)

          -  AML-MD (WHO classification)

          -  Treatment with minimum three to six cycles of Azacitidine

          -  Informed consent form signed

        Exclusion Criteria:

          -  Treatment with others chemotherapies alone or in association
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CH d'Antibes</name>
      <address>
        <city>Antibes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vanina OLIVERI, Project Manaer</last_name>
      <email>oliveri.v@chu-nice.fr</email>
    </contact>
    <investigator>
      <last_name>Daniel RE, PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nice - Hôpital de l'Archet</name>
      <address>
        <city>Nice</city>
        <zip>06200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vanina OLIVERI, Project Manager</last_name>
      <email>oliveri.v@chu-nice.fr</email>
    </contact>
    <investigator>
      <last_name>Thomas CLUZEAU, PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vanina OLIVERI, Project Manager</last_name>
      <email>oliveri.v@chhu-nice.fr</email>
    </contact>
    <investigator>
      <last_name>Antoine THYSS, PU-PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Frederic PEYRADE, PH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lauris GASTAUD, PH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Princesse Grace</name>
      <address>
        <city>Monaco</city>
        <country>Monaco</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vanina OLIVERI, Project Manager</last_name>
      <email>oliveri.v@chu-nice.fr</email>
    </contact>
    <investigator>
      <last_name>Georges GARNIER, PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philippe HEUDIER, PH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>Monaco</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <lastchanged_date>August 2, 2016</lastchanged_date>
  <firstreceived_date>September 27, 2010</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Azacitidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
